Abcuro, Inc.
Abcuro is a biotechnology company dedicated to developing breakthrough therapies for autoimmune diseases and cancer. Their mission is to precisely modulate cytotoxic T cells to treat serious autoimmune conditions and cancers, including inclusion body myositis, T cell large granular lymphocytic leukemia, and T and NK cell lymphomas. They focus on innovative monoclonal antibodies like ulviprubart that target specific immune cell markers, aiming to deplete pathogenic T cells while sparing protective ones.
Industries
Nr. of Employees
small (1-50)
Abcuro, Inc.
Patents
Methods of treating disorders associated with excess or unwanted killer cell lectin-like receptor subfamily g member 1 (KLRG1) expressing t cells with KLRG1 depleting antibodies
US-12139541-B2
View DetailsKiller cell lectin-like receptor subfamily G member 1 (KLRG1) depleting antibodies
US-11180561-B2
View Details
Methods of treating disorders associated with excess or unwanted killer cell lectin-like receptor subfamily g member 1 (KLRG1) expressing t cells with KLRG1 depleting antibodies
US-12139541-B2
View DetailsKiller cell lectin-like receptor subfamily G member 1 (KLRG1) depleting antibodies
US-11180561-B2
View DetailsProducts
Investigational monoclonal antibody targeting KLRG1 (lead clinical candidate)
A clinical-stage monoclonal antibody developed to selectively deplete KLRG1-expressing highly differentiated cytotoxic T cells, intended for treatment of certain autoimmune diseases and T/NK-cell malignancies.
Investigational monoclonal antibody targeting KLRG1 (lead clinical candidate)
A clinical-stage monoclonal antibody developed to selectively deplete KLRG1-expressing highly differentiated cytotoxic T cells, intended for treatment of certain autoimmune diseases and T/NK-cell malignancies.
Expertise Areas
- Clinical trial management (Phase 1–3 and long-term extension studies)
- Pharmacokinetics and pharmacodynamics
- Biologics CMC and process development
- Downstream purification and analytical development
Key Technologies
- Monoclonal antibody therapeutics
- Antibody targeting of inhibitory immune checkpoint receptors
- Radiolabeled PET imaging agents (zirconium-89 tracers)
- Pharmacokinetics / pharmacodynamics analysis
News & Updates
Ms. Cupples brings extensive global commercial leadership and rare disease product launch experience.
The company will present data from the Phase 1 clinical trial evaluating ulviprubart for the treatment of inclusion body myositis.
The company raised $200 million to support the completion of the Phase 2/3 MUSCLE trial and other development activities.
The trial enrollment has been completed to evaluate ulviprubart in IBM patients.
The FDA granted orphan drug status to ABC008 for the treatment of IBM.
Ms. Cupples brings extensive global commercial leadership and rare disease product launch experience.
The company will present data from the Phase 1 clinical trial evaluating ulviprubart for the treatment of inclusion body myositis.
The company raised $200 million to support the completion of the Phase 2/3 MUSCLE trial and other development activities.
The trial enrollment has been completed to evaluate ulviprubart in IBM patients.
The FDA granted orphan drug status to ABC008 for the treatment of IBM.